{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:34:32Z","timestamp":1789878872979,"version":"4.0.1"},"reference-count":235,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"am","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.therap.2023.09.010","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:48:27Z","timestamp":1698792507000},"page":"221-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Drug-induced hyperglycemia and diabetes"],"prefix":"10.1016","volume":"79","author":[{"given":"Marie-Anne","family":"Heurtebize","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Faillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.09.010_bib1000","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40264-015-0339-z","article-title":"Drug-induced hyperglycaemia and diabetes","volume":"38","author":"Fathallah","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2023.09.010_bib1005","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cpt.274","article-title":"Drug-induced diabetes mellitus: evidence for statins and other drugs affecting glucose metabolism","volume":"99","author":"Anyanwagu","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2023.09.010_bib1010","doi-asserted-by":"crossref","first-page":"e000801","DOI":"10.1136\/bmjdrc-2019-000801","article-title":"Medication-induced hyperglycemia: pediatric perspective","volume":"8","author":"Tosur","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.therap.2023.09.010_bib1015","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12272-018-1039-x","article-title":"Drug-induced hyperglycaemia and diabetes: pharmacogenomics perspectives","volume":"41","author":"Liu","year":"2018","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.therap.2023.09.010_bib1020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"key":"10.1016\/j.therap.2023.09.010_bib1025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case\u2013non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.09.010_bib1030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The Medical Dictionary for Regulatory Activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2023.09.010_bib1035","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.09.010_bib1040","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.09.010_bib1045","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","article-title":"Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative","volume":"172","author":"Culver","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1050","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jacc.2010.10.047","article-title":"Predictors of new-onset diabetes in patients treated with atorvastatin","volume":"57","author":"Waters","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.therap.2023.09.010_bib1055","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/CRD.0000000000000348","article-title":"Statins and higher diabetes mellitus risk: incidence, proposed mechanisms, and clinical implications","volume":"29","author":"Guber","year":"2021","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.therap.2023.09.010_bib1060","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.amjcard.2012.12.037","article-title":"Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus","volume":"111","author":"Navarese","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.therap.2023.09.010_bib1065","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2023.09.010_bib1070","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jacc.2012.05.019","article-title":"Statins, risk of diabetes, and implications on outcomes in the general population","volume":"60","author":"Wang","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.therap.2023.09.010_bib1075","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.09.010_bib1080","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2023.09.010_bib1085","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2125.2012.04403.x","article-title":"Statins and risk of treated incident diabetes in a primary care population: statins and risk of treated incident diabetes","volume":"75","author":"Zaharan","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.09.010_bib1090","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00125-006-0269-5","article-title":"Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control","volume":"49","author":"Nakata","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.therap.2023.09.010_bib1095","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.metabol.2014.02.014","article-title":"Statin treatment and new-onset diabetes: a review of proposed mechanisms","volume":"63","author":"Brault","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.therap.2023.09.010_bib1100","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.bjp.0702397","article-title":"Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca 2+ signalling and insulin secretion due to blockade of L-type Ca 2+ channels in rat islet \u03b2-cells: simvastatin on \u03b2-cell [Ca2 2+] i and insulin release","volume":"126","author":"Yada","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.therap.2023.09.010_bib1105","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.2337\/db13-1398","article-title":"Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance","volume":"63","author":"Henriksbo","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.therap.2023.09.010_bib1110","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4067\/S0034-98872014000200011","article-title":"Riesgo de diabetes mellitus tipo 2 asociado al uso de estatinas: evidencias y posibles mecanismos","volume":"142","author":"Suazo","year":"2014","journal-title":"Rev Med Chile"},{"key":"10.1016\/j.therap.2023.09.010_bib1115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1254\/jphs.FP0072403","article-title":"Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3t3l1 adipocytes","volume":"107","author":"Takaguri","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.therap.2023.09.010_bib1120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bcp.2015.11.023","article-title":"Involvement of pregnane X receptor in the impaired glucose utilization induced by atorvastatin in hepatocytes","volume":"100","author":"Ling","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.therap.2023.09.010_bib1125","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.apsb.2021.09.031","article-title":"PXR activation impairs hepatic glucose metabolism partly via inhibiting the HNF4\u03b1\u2013GLUT2 pathway","volume":"12","author":"Liu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.therap.2023.09.010_bib1130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0026-0495(64)90131-3","article-title":"The effect of nicotinic acid in diabetes mellitus","volume":"13","author":"Molnar","year":"1964","journal-title":"Metabolism"},{"key":"10.1016\/j.therap.2023.09.010_bib1135","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1210\/jc.2006-0913","article-title":"Impaired \u03b2-cell function in human aging: response to nicotinic acid-induced insulin resistance","volume":"91","author":"Chang","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib1140","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2147\/IJWH.S69908","article-title":"Niacin increased glucose, insulin, and C-peptide levels in sedentary nondiabetic postmenopausal women","volume":"6","author":"Koh","year":"2014","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.therap.2023.09.010_bib1145","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2337\/diab.38.5.562","article-title":"Increased \u03b2-Cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance","volume":"38","author":"Kahn","year":"1989","journal-title":"Diabetes"},{"key":"10.1016\/j.therap.2023.09.010_bib1150","first-page":"539","article-title":"Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on mild to moderate hypertension","volume":"2","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.09.010_bib1155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.09.010_bib1160","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/ajh.2008.17","article-title":"New onset diabetes during antihypertensive therapy","volume":"21","author":"Alderman","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.therap.2023.09.010_bib1165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/01.HYP.0000231552.10054.aa","article-title":"Thiazide diuretics, potassium, and the development of diabetes: a quantitative review","volume":"48","author":"Zillich","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.therap.2023.09.010_bib1170","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/erc.10.27","article-title":"Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics","volume":"8","author":"Duarte","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.therap.2023.09.010_bib1175","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2023.09.010_bib1180","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bcp.12543","article-title":"Quantifying the effects of diuretics and \u03b2-adrenoceptor blockers on glycaemic control in diabetes mellitus\u00a0\u2013\u00a0a systematic review and meta-analysis: diuretics and \u03b2-blockers on glycaemic control in diabetes","volume":"79","author":"Hirst","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.09.010_bib1185","article-title":"Acute and chronic effects of different concentrations of free fatty acids on the insulin secreting function of islets","volume":"28","author":"Ayvaz","year":"2002","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib1190","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ahj.2013.12.025","article-title":"Cardiovascular drugs that increase the risk of new-onset diabetes","volume":"167","author":"Ong","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.therap.2023.09.010_bib1195","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.therap.2023.09.010_bib1200","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/HYPERTENSIONAHA.111.189381","article-title":"A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension","volume":"59","author":"Stears","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.therap.2023.09.010_bib1205","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus","volume":"342","author":"Gress","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1210","first-page":"257","article-title":"Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial G\u00f6teborg, Sweden","volume":"8","author":"Samuelsson","year":"1994","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.therap.2023.09.010_bib1215","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2023.09.010_bib1220","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4330\/wjc.v6.i7.517","article-title":"Antihypertensive drugs and glucose metabolism","volume":"6","author":"Rizos","year":"2014","journal-title":"World J Cardiol"},{"key":"10.1016\/j.therap.2023.09.010_bib1225","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/ijo.2010.284","article-title":"Metabolic sequelae of \u03b2-blocker therapy: weighing in on the obesity epidemic?","volume":"35","author":"Lee","year":"2011","journal-title":"Int J Obes"},{"key":"10.1016\/j.therap.2023.09.010_bib1230","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/pgmj.73.864.640","article-title":"Diazoxide treatment for insulinoma: a national UK survey","volume":"73","author":"Gill","year":"1997","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.therap.2023.09.010_bib1235","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/diabetes.47.3.365","article-title":"Tolbutamide and diazoxide influence insulin secretion by changing the concentration but not the action of cytoplasmic Ca2+ in beta-cells","volume":"47","author":"Mariot","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.therap.2023.09.010_bib1240","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/106002809302700733","article-title":"Clonidine-induced hyperglycemia in a young diabetic girl","volume":"27","author":"Mimouni-Bloch","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.therap.2023.09.010_bib1245","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/00000542-199804000-00011","article-title":"Effects of oral clonidine premedication on plasma glucose and lipid homeostasis associated with exogenous glucose infusion in children","volume":"88","author":"Nishina","year":"1998","journal-title":"Anesthesiology"},{"key":"10.1016\/j.therap.2023.09.010_bib1250","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0002-9343(88)90006-X","article-title":"Encainide-induced hyperglycemia","volume":"84","author":"Salerno","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1255","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00246-004-0911-2","article-title":"Unusual and early hyperglycemia following amiodarone infusion in two infants","volume":"26","author":"Yildirim","year":"2005","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.therap.2023.09.010_bib1260","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0002-9343(84)91014-3","article-title":"Acute necrotizing pneumonitis and hyperglycemia after amiodarone therapy","volume":"76","author":"Pollak","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1265","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/bmj.288.6413.285","article-title":"Can amiodarone induce hyperglycaemia and hypertriglyceridaemia?","volume":"288","author":"Politi","year":"1984","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2023.09.010_bib1270","first-page":"259","article-title":"Encainide-induced diabetes: analysis of islet cell function","volume":"76","author":"Winter","year":"1992","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"10.1016\/j.therap.2023.09.010_bib1275","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.diabet.2007.01.003","article-title":"Abnormal glucose metabolism in patients treated with antipsychotics","volume":"33","author":"Scheen","year":"2007","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib1280","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14740338.2020.1713091","article-title":"Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis","volume":"19","author":"Barton","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.therap.2023.09.010_bib1285","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00125-022-05666-w","article-title":"When therapeutic drugs lead to diabetes","volume":"65","author":"F\u00e8ve","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.therap.2023.09.010_bib1290","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/wps.20069","article-title":"A meta-analysis of cardio-metabolic abnormalities in drug na\u00efve, first-episode and multi-episode patients with schizophrenia versus general population controls","volume":"12","author":"Vancampfort","year":"2013","journal-title":"World Psychiatry"},{"key":"10.1016\/j.therap.2023.09.010_bib1295","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/schbul\/sbs082","article-title":"Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.therap.2023.09.010_bib1300","doi-asserted-by":"crossref","first-page":"e150285","DOI":"10.1001\/jamapediatrics.2015.0285","article-title":"Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among medicaid-enrolled youths","volume":"169","author":"Rubin","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.therap.2023.09.010_bib1305","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.2337\/diacare.27.8.2088","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"Isaac","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl. 7","key":"10.1016\/j.therap.2023.09.010_bib1310","first-page":"4","article-title":"Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia","volume":"65","author":"Casey","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.therap.2023.09.010_bib1315","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2337\/diacare.26.5.1597","article-title":"Patients on atypical antipsychotic drugs","volume":"26","author":"Lean","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.therap.2023.09.010_bib1320","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/wps.20309","article-title":"Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis","volume":"15","author":"Vancampfort","year":"2016","journal-title":"World Psychiatry"},{"key":"10.1016\/j.therap.2023.09.010_bib1325","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrn3409","article-title":"Wired on sugar: the role of the CNS in the regulation of glucose homeostasis","volume":"14","author":"Grayson","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.therap.2023.09.010_bib1330","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11892-019-1220-8","article-title":"Association between antipsychotic medication use and diabetes","volume":"19","author":"Holt","year":"2019","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.therap.2023.09.010_bib1335","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejphar.2018.12.003","article-title":"Antipsychotics-induced metabolic alterations: recounting the mechanistic insights, therapeutic targets and pharmacological alternatives","volume":"844","author":"Singh","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.therap.2023.09.010_bib1340","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ecl.2013.05.006","article-title":"Effects of antipsychotic medications on appetite, weight, and insulin resistance","volume":"42","author":"Deng","year":"2013","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.therap.2023.09.010_bib1345","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40263-013-0115-5","article-title":"Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor","volume":"27","author":"Weston-Green","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.therap.2023.09.010_bib1350","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.therap.2023.09.010_bib1355","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamapsychiatry.2013.4030","article-title":"Diabetes risk potentially underestimated in youth and children receiving antipsychotics","volume":"71","author":"Samaras","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.therap.2023.09.010_bib1360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2014.11.008","article-title":"Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms","volume":"25","author":"Gon\u00e7alves","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.therap.2023.09.010_bib1365","doi-asserted-by":"crossref","first-page":"e125657","DOI":"10.1172\/jci.insight.125657","article-title":"The atypical antipsychotic quetiapine induces hyperlipidemia by activating intestinal PXR signaling","volume":"4","author":"Meng","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.therap.2023.09.010_bib1370","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.bbagrm.2016.03.012","article-title":"Regulation of hepatic energy metabolism by the nuclear receptor PXR","volume":"1859","author":"Hakkola","year":"2016","journal-title":"Biochim Biophys Acta BBA - Gene Regul Mech"},{"key":"10.1016\/j.therap.2023.09.010_bib1375","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc07-1827","article-title":"Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program","volume":"31","author":"Rubin","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.therap.2023.09.010_bib1380","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1176\/appi.ajp.2008.08071065","article-title":"Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus","volume":"166","author":"Andersohn","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.therap.2023.09.010_bib1385","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00228-007-0441-y","article-title":"The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports","volume":"64","author":"Derijks","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.09.010_bib1390","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.biopsych.2011.07.008","article-title":"Antidepressant medication use and risk of hyperglycemia and diabetes mellitus\u2014A noncausal association?","volume":"70","author":"Kivim\u00e4ki","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.therap.2023.09.010_bib1395","doi-asserted-by":"crossref","first-page":"110649","DOI":"10.1016\/j.diabres.2023.110649","article-title":"Antidepressant and antipsychotic drug prescribing and diabetes outcomes: a systematic review of observational studies","volume":"199","author":"Greene","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.therap.2023.09.010_bib1400","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s11096-011-9507-0","article-title":"Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports","volume":"33","author":"Khoza","year":"2011","journal-title":"Int J Clin Pharm"},{"issue":"Suppl. 8","key":"10.1016\/j.therap.2023.09.010_bib1405","first-page":"22","article-title":"Weight gain in the treatment of mood disorders","volume":"64","author":"Aronne","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.therap.2023.09.010_bib1410","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2337\/diacare.23.5.618","article-title":"Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial","volume":"23","author":"Lustman","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.therap.2023.09.010_bib1415","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.ijo.0800372","article-title":"Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss","volume":"21","author":"Maheux","year":"1997","journal-title":"Int J Obes"},{"key":"10.1016\/j.therap.2023.09.010_bib1420","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0269881107083798","article-title":"Review: bupropion and SSRI-induced side effects","volume":"22","author":"Demyttenaere","year":"2008","journal-title":"J Psychopharmacol (Oxf)"},{"key":"10.1016\/j.therap.2023.09.010_bib1425","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2337\/diab.20.3.177","article-title":"Diphenylhdantoin-induced hyperglycemia and impaired insulin release. Effect of dosage","volume":"20","author":"Fariss","year":"1971","journal-title":"Diabetes"},{"key":"10.1016\/j.therap.2023.09.010_bib1430","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1464-5491.1991.tb01539.x","article-title":"Phenytoin-induced insulin insensitivity","volume":"8","author":"Al-Rubeaan","year":"1991","journal-title":"Diabet Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1435","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1528-1167.2009.02206.x","article-title":"The metabolic syndrome in overweight epileptic patients treated with valproic acid","volume":"51","author":"Verrotti","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.therap.2023.09.010_bib1440","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/adc.46.248.563","article-title":"Hyperglycaemia due to phenytoin toxicity","volume":"46","author":"Treasure","year":"1971","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.therap.2023.09.010_bib1445","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/ped.13333","article-title":"Phenytoin-induced dysglycemia in a child","volume":"59","author":"Witthayapraphakorn","year":"2017","journal-title":"Pediatr Int"},{"key":"10.1016\/j.therap.2023.09.010_bib1450","first-page":"101","article-title":"Dysglycemia and fluoroquinolones: are you putting patients at risk?","volume":"56","author":"Catero","year":"2007","journal-title":"J Fam Pract"},{"key":"10.1016\/j.therap.2023.09.010_bib1455","first-page":"569","article-title":"Advancing age and renal impairment as important predisposing factors of gatifloxacin-induced hyperglycemia in non-diabetes patients","volume":"90","author":"Ovartlarnporn","year":"2007","journal-title":"J Med Assoc Thail Chotmaihet Thangphaet"},{"key":"10.1016\/j.therap.2023.09.010_bib1460","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/600294","article-title":"Severe dysglycemia with the fluoroquinolones: a class effect?","volume":"49","author":"Aspinall","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.therap.2023.09.010_bib1465","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJMoa055191","article-title":"Outpatient gatifloxacin therapy and dysglycemia in older adults","volume":"354","author":"Park-Wyllie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1470","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pcd.2014.10.006","article-title":"Dysglycemia associated with quinolones","volume":"9","author":"El Ghandour","year":"2015","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.therap.2023.09.010_bib1475","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/0976-0105.152100","article-title":"Isoniazid induced childhood diabetes: a rare phenomenon","volume":"6","author":"Manish","year":"2015","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.therap.2023.09.010_bib1480","first-page":"23","article-title":"Rifampicin-induced early phase hyperglycemia in humans","volume":"125","author":"Takasu","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.therap.2023.09.010_bib1485","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4103\/0971-4065.103930","article-title":"Fatal poisoning by isoniazid and rifampicin","volume":"22","author":"Sridhar","year":"2012","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.therap.2023.09.010_bib1490","doi-asserted-by":"crossref","first-page":"e2844","DOI":"10.1097\/MD.0000000000002844","article-title":"Risk factors for incident diabetes in a cohort taking first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy","volume":"95","author":"Karamchand","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.therap.2023.09.010_bib1495","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1345\/aph.10044","article-title":"Glucose disorders associated with HIV and its drug therapy","volume":"35","author":"Hardy","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.therap.2023.09.010_bib1500","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM200101113440216","article-title":"Abacavir and diabetes","volume":"344","author":"Modest","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1505","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.09.010_bib1510","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-199907090-00001","article-title":"Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors","volume":"13","author":"Behrens","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.therap.2023.09.010_bib1515","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2515\/therapie\/2010051","article-title":"Hyperglyc\u00e9mies d\u2019origine m\u00e9dicamenteuse\u00a0: \u00e9tude dans la base nationale fran\u00e7aise de pharmacovigilance (BNPV)","volume":"65","author":"Chebane","year":"2010","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.09.010_bib1520","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.molmed.2010.03.002","article-title":"HIV-associated lipodystrophy: from fat injury to premature aging","volume":"16","author":"Caron-Debarle","year":"2010","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1525","doi-asserted-by":"crossref","first-page":"E925","DOI":"10.1152\/ajpendo.90445.2008","article-title":"Protease inhibitors used in the treatment of HIV + induce \u03b2-cell apoptosis via the mitochondrial pathway and compromise insulin secretion","volume":"296","author":"Zhang","year":"2009","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib1530","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00126334-200106010-00006","article-title":"Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients","volume":"27","author":"Dub\u00e9","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.therap.2023.09.010_bib1535","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/19491034.2018.1456217","article-title":"Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives","volume":"9","author":"Vigouroux","year":"2018","journal-title":"Nucleus"},{"key":"10.1016\/j.therap.2023.09.010_bib1540","doi-asserted-by":"crossref","first-page":"36395","DOI":"10.1074\/jbc.M110.176321","article-title":"Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice","volume":"285","author":"Vyas","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.therap.2023.09.010_bib1545","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jval.2012.10.021","article-title":"Comparative incidence and health care costs of medically attended adverse effects among US Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy","volume":"16","author":"Johnston","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.therap.2023.09.010_bib1550","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes","volume":"71","author":"Gorwood","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.therap.2023.09.010_bib1555","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","article-title":"CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.therap.2023.09.010_bib1560","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/BF00577749","article-title":"Insulin-dependent diabetes mellitus following pentamidine therapy in a patient with AIDS","volume":"72","author":"Liegl","year":"1994","journal-title":"Clin Investig"},{"key":"10.1016\/j.therap.2023.09.010_bib1565","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/0002-9343(89)90457-9","article-title":"Pentamidine-induced pancreatic beta-cell dysfunction","volume":"86","author":"Shen","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1570","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2337\/diacare.18.1.47","article-title":"Pentamidine-induced derangements of glucose homeostasis: determinant roles of renal failure and drug accumulation: a study of 128 patients","volume":"18","author":"Assan","year":"1995","journal-title":"Diabetes Care"},{"key":"10.1016\/j.therap.2023.09.010_bib1575","doi-asserted-by":"crossref","first-page":"587","DOI":"10.5694\/j.1326-5377.1996.tb138654.x","article-title":"Diabetes mellitus associated with pentamidine use in HIV-infected patients","volume":"165","author":"Coyle","year":"1996","journal-title":"Med J Aust"},{"key":"10.1016\/j.therap.2023.09.010_bib1580","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.therap.2023.09.010_bib1585","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.therap.2023.09.010_bib1590","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S2213-8587(19)30072-5","article-title":"Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome","volume":"7","author":"Perdigoto","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.therap.2023.09.010_bib1595","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.therap.2023.09.010_bib1600","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1634\/theoncologist.2019-0806","article-title":"Cases from the immune-related adverse event tumor board: diagnosis and management of immune checkpoint blockade-induced diabetes","volume":"25","author":"Zagouras","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.therap.2023.09.010_bib1605","doi-asserted-by":"crossref","first-page":"e3366","DOI":"10.1002\/dmrr.3366","article-title":"Diabetes mellitus induced by immune checkpoint inhibitors","volume":"37","author":"Zheng","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.therap.2023.09.010_bib1610","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.therap.2023.09.010_bib1615","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-016-0485-y","article-title":"Hyperglycaemia induced by novel anticancer agents: an undesirable complication or a potential therapeutic opportunity?","volume":"40","author":"Shah","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2023.09.010_bib1620","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/jdi.13168","article-title":"Ceritinib-associated hyperglycemia in the Japanese Adverse Drug Event Report Database","volume":"11","author":"Fujita","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.therap.2023.09.010_bib1625","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.2147\/OTT.S193951","article-title":"Safety and efficacy of brentuximab vedotin in the treatment of classic hodgkin lymphoma","volume":"13","author":"Makita","year":"2020","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.therap.2023.09.010_bib1630","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00280-013-2240-8","article-title":"Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer","volume":"72","author":"Doi","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.therap.2023.09.010_bib1635","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bcp.12228","article-title":"The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy: adverse events caused by anti-IGF-1R monoclonal antibodies","volume":"77","author":"Ma","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.09.010_bib1640","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.1158\/1078-0432.CCR-10-3336","article-title":"A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors","volume":"17","author":"Atzori","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.therap.2023.09.010_bib1645","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s13410-022-01116-w","article-title":"Brentuximab vedotin-associated diabetic ketoacidosis: a case report","volume":"43","author":"K\u00f6ksalan","year":"2023","journal-title":"Int J Diabetes Dev Ctries"},{"key":"10.1016\/j.therap.2023.09.010_bib1650","first-page":"441","article-title":"Diabetic ketoacidosis and persistent hyperglycemia as long-term complications of L-asparaginase-induced pancreatitis","volume":"65","author":"Hsu","year":"2002","journal-title":"Zhonghua Yi Xue Za Zhi (Taipei)"},{"key":"10.1016\/j.therap.2023.09.010_bib1655","first-page":"735","article-title":"Diabetic ketoacidosis with L-asparaginase therapy","volume":"48","author":"Mondal","year":"2011","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.therap.2023.09.010_bib1660","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/pbc.21505","article-title":"Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia","volume":"50","author":"Roberson","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.therap.2023.09.010_bib1665","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0277-5379(84)90031-2","article-title":"Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects","volume":"20","author":"Alexieva-Figusch","year":"1984","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.therap.2023.09.010_bib1670","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/pgmj.72.848.365","article-title":"Insulin resistance and development of diabetes mellitus associated with megestrol acetate therapy","volume":"72","author":"Jain","year":"1996","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.therap.2023.09.010_bib1675","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4103\/0976-500X.189684","article-title":"Cyclophosphamide and epirubicin-induced diabetes mellitus in breast cancer: a rare occurrence","volume":"7","author":"Sharma","year":"2016","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1016\/j.therap.2023.09.010_bib1680","doi-asserted-by":"crossref","first-page":"E343","DOI":"10.1188\/14.ONF.E343-E354","article-title":"Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors: a review of the literature","volume":"41","author":"Hershey","year":"2014","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.therap.2023.09.010_bib1685","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1200\/JCO.2008.19.1098","article-title":"Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma","volume":"27","author":"Derr","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.therap.2023.09.010_bib1690","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s10637-014-0066-9","article-title":"Phase II trial of vorinostat in advanced melanoma","volume":"32","author":"Haas","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.therap.2023.09.010_bib1695","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13050","article-title":"Safety and clinical activity of 5-aza-2\u2032-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed\/refractory acute lymphocytic leukaemia","volume":"167","author":"Benton","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.therap.2023.09.010_bib1700","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s10637-014-0111-8","article-title":"Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Gro*up","volume":"32","author":"Ciombor","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.therap.2023.09.010_bib1705","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1463-1318.2012.03097.x","article-title":"Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study: diabetes associated with 5-FU chemotherapy","volume":"15","author":"Feng","year":"2013","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.therap.2023.09.010_bib1710","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/jcsm.12104","article-title":"Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPk signalling in skeletal muscle: doxorubicin caused severe hyperglycaemia and insulin resistance","volume":"7","author":"De Lima Junior","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.therap.2023.09.010_bib1715","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ctrv.2015.02.007","article-title":"Cancer-drug induced insulin resistance: innocent bystander or unusual suspect","volume":"41","author":"Ariaans","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.therap.2023.09.010_bib1720","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(05)60474-6","article-title":"A cyclophosphamide-induced autoimmune diabetes","volume":"352","author":"Atlan-Gepner","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.09.010_bib1725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s004670200000","article-title":"Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis","volume":"17","author":"Greenspan","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.therap.2023.09.010_bib1730","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1262-3636(06)72809-9","article-title":"Immunosuppressive drug-induced diabetes","volume":"32","author":"Penfornis","year":"2006","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib1735","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cpt.546","article-title":"Calcineurin inhibitors: pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus","volume":"101","author":"Chakkera","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2023.09.010_bib1740","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1681\/ASN.V131221","article-title":"Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction","volume":"13","author":"Boots","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.09.010_bib1745","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","article-title":"New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis","volume":"4","author":"Heisel","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.therap.2023.09.010_bib1750","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1681\/ASN.2006030196","article-title":"Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes?","volume":"17","author":"Di Paolo","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.09.010_bib1755","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.tp.0000195770.31960.18","article-title":"Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs","volume":"81","author":"Araki","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.therap.2023.09.010_bib1760","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1158\/1940-6207.CAPR-11-0023","article-title":"Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer","volume":"4","author":"Lashinger","year":"2011","journal-title":"Cancer Prev Res (Phila Pa)"},{"key":"10.1016\/j.therap.2023.09.010_bib1765","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1507\/endocrj.EJ18-0553","article-title":"Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report database: association of evelolimus use with diabetes","volume":"66","author":"Konishi","year":"2019","journal-title":"Endocr J"},{"key":"10.1016\/j.therap.2023.09.010_bib1770","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1681\/ASN.2007111202","article-title":"Sirolimus is associated with new-onset diabetes in kidney transplant recipients","volume":"19","author":"Johnston","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.09.010_bib1775","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1681\/ASN.2005050487","article-title":"Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus","volume":"16","author":"Teutonico","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.09.010_bib1780","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.transproceed.2004.04.044","article-title":"Long-term outcome of sirolimus rescue in kidney\u2013pancreas transplantation","volume":"36","author":"Rogers","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.therap.2023.09.010_bib1785","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2217\/fon.14.136","article-title":"Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis","volume":"11","author":"Abdel-Rahman","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.therap.2023.09.010_bib1790","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2014.58.8871","article-title":"Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma","volume":"33","author":"Oza","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.therap.2023.09.010_bib1795","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2013.12.013","article-title":"Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature","volume":"91","author":"Abdel-Rahman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.therap.2023.09.010_bib1800","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1586\/14737140.2014.894465","article-title":"Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis","volume":"14","author":"Abdel-Rahman","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.therap.2023.09.010_bib1805","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00109-011-0834-3","article-title":"Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity","volume":"90","author":"Yang","year":"2012","journal-title":"J Mol Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1810","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.molmet.2014.06.004","article-title":"Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo","volume":"3","author":"Kleinert","year":"2014","journal-title":"Mol Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib1815","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.therap.2023.09.010_bib1820","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2337\/db07-0922","article-title":"mTOR Inhibition by rapamycin prevents \u03b2-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes","volume":"57","author":"Fraenkel","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.therap.2023.09.010_bib1825","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.diabres.2018.04.001","article-title":"Everolimus is a new anti-cancer molecule: metabolic side effects as lipid disorders and hyperglycemia","volume":"143","author":"Morviducci","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.therap.2023.09.010_bib1830","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1097\/TP.0000000000001722","article-title":"mTOR and cardiovascular diseases: diabetes mellitus","volume":"102","author":"Verg\u00e8s","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.therap.2023.09.010_bib1835","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1126\/science.1215135","article-title":"Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity","volume":"335","author":"Lamming","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.therap.2023.09.010_bib1840","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.therap.2023.09.010_bib1845","doi-asserted-by":"crossref","first-page":"33085","DOI":"10.1074\/jbc.274.46.33085","article-title":"Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin","volume":"274","author":"Taha","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.therap.2023.09.010_bib1850","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.transproceed.2007.06.021","article-title":"Do anti-CD25 monoclonal antibodies potentiate posttransplant diabetes mellitus?","volume":"39","author":"Bay\u00e9s","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.therap.2023.09.010_bib1855","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/nep.12209","article-title":"Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients?","volume":"19","author":"Prasad","year":"2014","journal-title":"Nephrology"},{"key":"10.1016\/j.therap.2023.09.010_bib1860","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2337\/diacare.26.4.1322-a","article-title":"Thalidomide-associated hyperglycemia and diabetes","volume":"26","author":"Pathak","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.therap.2023.09.010_bib1865","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0093-7754(01)90157-5","article-title":"A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer","volume":"28","author":"Figg","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.therap.2023.09.010_bib1870","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2337\/diacare.23.8.1172","article-title":"Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes","volume":"23","author":"Iqbal","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.therap.2023.09.010_bib1875","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/archderm.144.10.1403","article-title":"Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis","volume":"144","author":"Wu","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.09.010_bib1880","doi-asserted-by":"crossref","first-page":"51","DOI":"10.21315\/mjms2018.25.4.5","article-title":"Effects of adalimumab, an anti-tumour necrosis factor-alpha (TNF-\u03b1) antibody, on obese diabetic rats","volume":"25","author":"Shuwa","year":"2018","journal-title":"Malays J Med Sci"},{"key":"10.1016\/j.therap.2023.09.010_bib1885","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.2011.878","article-title":"Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis","volume":"305","author":"Solomon","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2023.09.010_bib1890","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jcb.26174","article-title":"Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus","volume":"119","author":"Akash","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.therap.2023.09.010_bib1895","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2036.2009.04071.x","article-title":"Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection","volume":"30","author":"Panetta","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.therap.2023.09.010_bib1900","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2036.2003.01681.x","article-title":"Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy: type 1 diabetes mellitus in patients with chronic hepatitis C","volume":"18","author":"Fabris","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.therap.2023.09.010_bib1905","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","article-title":"Side effects of high-dose interferon therapy for chronic hepatitis C","volume":"25","author":"Okanoue","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.therap.2023.09.010_bib1910","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0168-8278(96)80184-X","article-title":"A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon","volume":"24","author":"Fattovich","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.therap.2023.09.010_bib1915","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/(SICI)1096-9136(199805)15:5<435::AID-DIA566>3.0.CO;2-N","article-title":"Hyperglycaemia due to insulin resistance caused by interferon-\u03b3","volume":"15","author":"Shiba","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1920","first-page":"549","article-title":"Salbutamol intoxication","volume":"132","author":"Danenberg","year":"1997","journal-title":"Harefuah"},{"key":"10.1016\/j.therap.2023.09.010_bib1925","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/bmj.2.6084.438","article-title":"Salbutamol-induced diabetic ketoacidosis","volume":"2","author":"Thomas","year":"1977","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2023.09.010_bib1930","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1651-2227.1995.tb13633.x","article-title":"Acute asthma, salbutamol and hyperglycaemia","volume":"84","author":"Dawson","year":"1995","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.therap.2023.09.010_bib1935","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ppul.20263","article-title":"Effect of nebulized albuterol on blood glucose in patients with diabetes mellitus with and without cystic fibrosis","volume":"40","author":"K\u00f6nig","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.therap.2023.09.010_bib1940","first-page":"71","article-title":"Mechanisms of abnormal glucose metabolism during the treatment of acute severe asthma","volume":"82","author":"Smith","year":"1992","journal-title":"Q J Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1945","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3904\/kjim.2002.17.2.147","article-title":"Lactic acidosis associated with the usual theophylline dose in a patient with asthma","volume":"17","author":"Koh","year":"2002","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1950","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-3476(05)82558-2","article-title":"Effect of acute versus chronic intoxication on clinical features of theophylline poisoning in children","volume":"121","author":"Shannon","year":"1992","journal-title":"J Pediatr"},{"key":"10.1016\/j.therap.2023.09.010_bib1955","doi-asserted-by":"crossref","first-page":"766","DOI":"10.7326\/0003-4819-102-6-766","article-title":"Theophylline toxicity and the beta-adrenergic system","volume":"102","author":"Kearney","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.therap.2023.09.010_bib1960","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0091-6749(82)90028-8","article-title":"Stimulation of endogenous catecholamine release by theophylline: a proposed additional mechanism of action for theophylline effects","volume":"70","author":"Higbee","year":"1982","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.therap.2023.09.010_bib1965","doi-asserted-by":"crossref","first-page":"e2671","DOI":"10.1210\/clinem\/dgac231","article-title":"Prolonged use of proton pump inhibitors and risk of type 2 diabetes: results from a large population-based nested case-control study","volume":"107","author":"Ciardullo","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib1970","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3803\/EnM.2017.32.2.180","article-title":"Glucocorticoid-induced diabetes mellitus: an important but overlooked problem","volume":"32","author":"Suh","year":"2017","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib1975","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000365892","article-title":"Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis","volume":"65","author":"Liu","year":"2014","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib1980","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/BF00860958","article-title":"Non-ketotic hyperosmolar coma complicating steroid treatment in childhood nephrosis","volume":"9","author":"Yang","year":"1995","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.therap.2023.09.010_bib1985","first-page":"1044","article-title":"In-hospital cardiac arrest due to unobserved steroid-induced hyperglycaemic hyperosmolar syndrome","volume":"175","author":"Jensen","year":"2013","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.therap.2023.09.010_bib1990","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/rheumatology\/kes003","article-title":"Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study","volume":"51","author":"Burt","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.therap.2023.09.010_bib1995","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-014-0282-9","article-title":"Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events","volume":"74","author":"Fardet","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.therap.2023.09.010_bib2000","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1210\/jc.2010-2729","article-title":"Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD","volume":"96","author":"Burt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib2005","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcp.12637","article-title":"Inhaled corticosteroids: potency, dose equivalence and therapeutic index","volume":"80","author":"Daley-Yates","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.09.010_bib2010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/pmrj.12042","article-title":"Systemic absorption and side effects of locally injected glucocorticoids","volume":"11","author":"Stout","year":"2019","journal-title":"PM&R"},{"key":"10.1016\/j.therap.2023.09.010_bib2015","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI119743","article-title":"Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids","volume":"100","author":"Delaunay","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.therap.2023.09.010_bib2020","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1210\/jc.2010-0119","article-title":"Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects","volume":"95","author":"Hansen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib2025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1054\/clnu.1999.0064","article-title":"Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man","volume":"19","author":"Dirlewanger","year":"2000","journal-title":"Clin Nutr"},{"key":"10.1016\/j.therap.2023.09.010_bib2030","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1172\/JCI116803","article-title":"Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats","volume":"92","author":"Saad","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.therap.2023.09.010_bib2035","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cmet.2013.05.020","article-title":"Human but not mouse adipogenesis is critically dependent on LMO3","volume":"18","author":"Lindroos","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib2040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2265.2012.04348.x","article-title":"Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy","volume":"78","author":"Fardet","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.therap.2023.09.010_bib2045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0010-7824(98)00018-3","article-title":"Safety evaluation of modern oral contraceptives","volume":"57","author":"Crook","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.therap.2023.09.010_bib2050","article-title":"Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus","author":"Lopez","year":"20142019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2023.09.010_bib2055","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.1158\/0008-5472.CAN-08-0553","article-title":"Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer","volume":"68","author":"Johansson","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.therap.2023.09.010_bib2060","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jcem.87.1.8168","article-title":"Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial","volume":"87","author":"Andersson","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.therap.2023.09.010_bib2065","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.fertnstert.2007.03.083","article-title":"Effects of raloxifene on insulin sensitivity, \u03b2-cell function, and hepatic insulin extraction in normal postmenopausal women","volume":"89","author":"Nagamani","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.therap.2023.09.010_bib2070","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3109\/09513590.2013.788628","article-title":"Raloxifene modifies the insulin sensitivity and lipid profile of postmenopausal insulin resistant women","volume":"29","author":"Grover-P\u00e1ez","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.therap.2023.09.010_bib2075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1365-2265.2005.02205.x","article-title":"Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels","volume":"62","author":"Dougherty","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.therap.2023.09.010_bib2080","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrendo.2011.242","article-title":"Importance of oestrogen receptors to preserve functional \u03b2-cell mass in diabetes","volume":"8","author":"Tiano","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.therap.2023.09.010_bib2085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11154-011-9182-4","article-title":"Metabolic effects of contraceptive steroids","volume":"12","author":"Sitruk-Ware","year":"2011","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.therap.2023.09.010_bib2090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1464-5491.2011.03430.x","article-title":"Oral contraception enhances growth hormone responsiveness to hyper- and hypoglycaemia: effects of oral contraceptives on growth hormone response","volume":"29","author":"Friedrich","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.therap.2023.09.010_bib2095","series-title":"Sex and gender factors affecting metabolic homeostasis, diabetes and obesity","first-page":"473","article-title":"Negative impact of testosterone deficiency and 5\u03b1-reductase inhibitors therapy on metabolic and sexual function in men","author":"Traish","year":"2017"},{"key":"10.1016\/j.therap.2023.09.010_bib2100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fendo.2013.00064","article-title":"Adult growth hormone deficiency\u2013benefits, side effects, and risks of growth hormone replacement","volume":"4","author":"Reed","year":"2013","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.therap.2023.09.010_bib2105","doi-asserted-by":"crossref","unstructured":"Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000 ;355:610-3.","DOI":"10.1016\/S0140-6736(99)04055-6"},{"key":"10.1016\/j.therap.2023.09.010_bib2110","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jpeds.2013.04.045","article-title":"Metabolic safety of growth hormone in type 1 diabetes and idiopathic growth hormone deficiency","volume":"163","author":"Bonfig","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.therap.2023.09.010_bib2115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/153537020222700301","article-title":"Growth hormone-induced alterations in the insulin-signaling system","volume":"227","author":"Dominici","year":"2002","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.therap.2023.09.010_bib2120","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-3476(94)70221-7","article-title":"Hyperglycemia during replacement growth hormone therapy","volume":"125","author":"Garg","year":"1994","journal-title":"J Pediatr"},{"key":"10.1016\/j.therap.2023.09.010_bib2125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0218492316682670","article-title":"Octreotide use in post-cardiac surgery chylothorax: a 12-year perspective","volume":"25","author":"Aljazairi","year":"2017","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"10.1016\/j.therap.2023.09.010_bib2130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/pbc.22838","article-title":"Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease: octreotide in chemotherapy induced diarrhea","volume":"56","author":"Pai","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.therap.2023.09.010_bib2135","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-0034-1376988","article-title":"Long-term medical treatment of Cushing's disease with pasireotide: a review of current evidence and clinical experience","volume":"122","author":"Samson","year":"2014","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.therap.2023.09.010_bib2140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(99)90040-5","article-title":"Hype about glucosamine","volume":"354","author":"Adams","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.09.010_bib2145","first-page":"239","article-title":"Diamox and manifestation of diabetes mellitus","volume":"118","author":"Kurz","year":"1968","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.therap.2023.09.010_bib2150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1210\/endo-107-2-461","article-title":"Morphine-induced hyperglycemia: role of insulin and glucagon*","volume":"107","author":"Ipp","year":"1980","journal-title":"Endocrinology"},{"key":"10.1016\/j.therap.2023.09.010_bib2155","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2023.09.010_bib2160","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"Begaud","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2023.09.010_bib2165","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/pds.2022","article-title":"A potential competition bias in the detection of safety signals from spontaneous reporting databases","volume":"19","author":"Pariente","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2023.09.010_bib2170","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.maturitas.2017.08.006","article-title":"Drugs and hyperglycemia: a practical guide","volume":"104","author":"Jain","year":"2017","journal-title":"Maturitas"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:51:30Z","timestamp":1730436690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723001749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":235,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0040595723001749"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.09.010","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced hyperglycemia and diabetes","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}